Documente Academic
Documente Profesional
Documente Cultură
Takayasu Arteritis
It Is Time to Work Together
Joshua A. Beckman, MD
Japanese ophthalmologist that meets the Orphan Drug Act def- women. To understand the value of this report, it must be made
inition in the United State but may be more prevalent in Japan; clear that the group of newly diagnosed patients in this report
autopsy series show evidence of TA in 1 of 3000 people.2 The may be 10-fold larger than in any other similar publication of
disease is one of vascular inflammation with destruction of new patient presentations. These data will further refine our
elastic fibers, vascular smooth muscle, and vessel wall matrix understanding of the presentation of TA, increase awareness
components. Arterial stenosis remains the most common vas- of low-frequency sequelae present in Japanese patients, and
cular presentation; however, aortic aneurysmal disease has provide a pathway for others to follow in data collection.
been reported in as many as one quarter of patients. The varia- The report by Mekinian and colleagues4 demonstrates the
tion by nationality in incidence, clinical characteristics, and hard work necessary to advance disease therapeutics. In this
female/male ratio suggests a genetic component to the disease, retrospective study, the investigators determined the outcome
but no reliable marker has been identified. The most common of TA patients treated with tumor necrosis factor-α antagonists
time of diagnosis is the second and third decades of life. In the or tocilizumab, an interleukin-6 receptor antagonist. Of the 49
United States, the age of the patient is important, for it is one patients reported, 88% were inadequately controlled by stan-
method of distinguishing TA from giant-cell arteritis, which is dard therapy. The response to these agents significantly lowered
commonly diagnosed in the eighth decade of life but has many markers of inflammation, reduced daily prednisone require-
signs and symptoms overlapping those of TA. Patients who ments, tended to reduce vascular complications, and improved
present with symptoms of inflammation or arterial occlusive relapse-free survival to 90% at 3 years. These data affirm the
disease in the fifth and early sixth decades of life present a use of the tumor necrosis factor-α and interleukin-6 receptor
diagnostic challenge in determining the diagnosis. antagonists in TA. Unfortunately, because of the lack of pro-
Despite the yeoman’s work of many in the field, the lim- spective data collection and disposition of treating physicians,
ited patient numbers and modest efforts to accrue larger num- these data carry the burdens of a retrospective trial and cannot
bers of patients across centers have slowed our understanding confirm the value of these agents. Still, the data are reassuring.
of the disease. As with many other rare diseases, the lack of The care of patients with TA and other large-vessel vas-
animal models of disease, lack of large patient numbers in any culitides would benefit from 2 interventions. The first is
one center, and limited clinical development pathway render the development of an ongoing registry to aggregate cases
investigation more difficult and interpretation of small data in the United States. Two diseases provide strong models
sets challenging. It is with this background that the 2 publica- for this: aortic dissection and fibromuscular dysplasia. The
tions in this issue of Circulation are so welcome.
International Registry of Acute Aortic Dissections, organized
Watanabe and colleagues3 have analyzed 1372 newly reg-
in 1996, now has participating centers in >11 nations and has
istered patients with TA collected over 10 years in Japan. In
enrolled nearly 6000 patients with aortic dissection.5 In addi-
tion to significantly improving the understanding of disease
The opinions expressed in this article are not necessarily those of the presentation and outcome, this registry has now embarked on
editors or of the American Heart Association. clinical research to improve disease management with a com-
From Vanderbilt University, Nashville, TN.
Correspondence to Joshua A. Beckman, MD, Vanderbilt University, mitted group of investigators already used to working together.
1215 21st Ave S, Medical Center East, 5th Floor, South Tower, Nashville, A registry for fibromuscular dysplasia was organized in 2007
TN 37232–8802. E-mail joshua.a.beckman@vanderbilt.edu with the first online database patient entry in 2009. Three years
(Circulation. 2015;132:1685-1686.
DOI: 10.1161/CIRCULATIONAHA.115.018895.) later, the group published findings on 447 patients and has
© 2015 American Heart Association, Inc. provided insights into this disease that previously were undis-
Circulation is available at http://circ.ahajournals.org covered.6 Neither of these 2 registries was flush with resources
DOI: 10.1161/CIRCULATIONAHA.115.018895 or funds; what they had were clinician scientists interested in
1685
1686 Circulation November 3, 2015
doomed to rely on heroic retrospective evaluation of presenta- CJ, Gornik HL. The United States Registry for Fibromuscular Dysplasia:
tion and treatment efficacy. results in the first 447 patients. Circulation. 2012;125:3182–3190. doi:
10.1161/CIRCULATIONAHA.112.091223.
Disclosures
None. Key Words: Editorials ◼ aneurysm ◼ inflammation ◼ Takayasu arteritis
Takayasu Arteritis: It Is Time to Work Together
Joshua A. Beckman
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539
The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/132/18/1685
Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.